Luaran Klinis Pneumonia Akibat Pseudomonas Aeruginosa Extensively Drug-Resistant Pada Pasien Lansia Pasca-Stroke: Laporan Kasus Berbasis Bukti
DOI:
https://doi.org/10.55606/jurrikes.v5i1.8549Keywords:
extensively drug-resistant, Pseudomonas aeruginosa, pneumonia, outcomes, stroke-associated pneumoniaAbstract
Pneumonia caused by extensively drug-resistant (XDR) Pseudomonas aeruginosa is still clinicaly chalenging, particularly among geriatric patients with neurological comorbidities such as stroke. This report presents a case of XDR P. aeruginosa pneumonia complicated by sepsis in a 73-year-old patient, characterized by persistent leukocytosis until the tenth day of hospitalization despite empirical meropenem therapy. This evidence-based case report aims to analyze clinical outcomes, specifically 28-day and 30-day mortality rates, and to identify mortality predictors in the adult population through a systematic literature search of the PubMed and Google Scholar databases for the 2019–2026 period. Synthesized evidence from six core studies indicates that XDR P. aeruginosa infections carry a profoundly high 28-day mortality rate, ranging from 41% to 51% in cohorts receiving antibiotic monotherapy. Key mortality predictors identified include the presence of sepsis or septic shock, a delay in initiating adequate therapy exceeding 52 hours, advanced age, and the requirement for Intensive Care Unit (ICU) admission. The phenomenon of persistent or worsening leukocytosis during treatment, as observed in this case, serves as a critical clinical indicator associated with antimicrobial response failure and a dismal prognosis. Ultimately, XDR P. aeruginosa pneumonia is associated with poor clinical outcomes, where therapeutic success is strictly contingent upon the timely administration of antibiotic regimens with proven activity against these highly resistant isolates.
Downloads
References
Abdelrahman, A., Hassanein, M., Fouad, M., Abdel Hamid, M., Dawoud, A., & Samy, A. (2024). Bacterial stroke-associated pneumonia: Microbiological analysis and mortality outcome. BMC Neurology, 24, 282. https://doi.org/10.1186/s12883-024-03755-4
Chauhan, Y., & Trivedi, N. (2023). Surveillance of healthcare-associated Pseudomonas aeruginosa infections in a tertiary care teaching hospital. QAI Journal of Healthcare Quality and Patient Safety, 4(1), 12–16. https://doi.org/10.4103/QAIJ.QAIJ_6_23
Chen, Y., Liu, Y., Zhang, X., Wang, L., Li, J., Zhou, H., et al. (2023). Epidemiology, antimicrobial resistance, and risk factors for mortality of Pseudomonas aeruginosa infections in hospitalized patients. Frontiers in Public Health, 11, 1243973. https://doi.org/10.3389/fpubh.2023.1243973
de Jonge, J. C., van de Beek, D., Lyden, P., Brady, M. C., Bath, P. M., & van der Worp, H. B. (2022). Temporal profile of pneumonia after stroke. Stroke, 53(1), 53–60. https://doi.org/10.1161/STROKEAHA.120.032787
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., et al. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa. mBio, 15(2), e0316523. https://doi.org/10.1128/mbio.03165-23
Ioannou, P., Alexakis, K., Maraki, S., & Kofteridis, D. P. (2023). Pseudomonas aeruginosa bacteremia in a tertiary hospital and factors associated with mortality. Antibiotics, 12(4), 670. https://doi.org/10.3390/antibiotics12040670
Kang, Y., Zhang, Z., & Cui, J. (2026). Clinical risk factors, antimicrobial therapy, and virulence-associated mortality in patients with extensively drug-resistant or pan-drug-resistant (XDR/PDR) Pseudomonas aeruginosa pulmonary infections. International Journal of Infectious Diseases, 162, 108198. https://doi.org/10.1016/j.ijid.2025.108198
Khwannimit, B., Bhurayanontachai, R., & Vattanavanit, V. (2024). Evaluation of risk factors for 14-day and 30-day mortality among treatment regimens against Pseudomonas aeruginosa resistant to carbapenem but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents. PLoS ONE, 19(11), e0313944. https://doi.org/10.1371/journal.pone.0313944
Kishore, A. K., Vail, A., Chamorro, A., Garau, J., Hopkins, S. J., Di Napoli, M., et al. (2018). Microbiological etiologies of pneumonia complicating stroke: A systematic review. Stroke, 49(7), 1602–1610. https://doi.org/10.1161/STROKEAHA.118.020234
Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022). Therapeutic strategies for emerging multidrug-resistant Pseudomonas aeruginosa. Infectious Diseases and Therapy, 11(2), 661–682. https://doi.org/10.1007/s40121-022-00591-2
Lameng, I. S. V., Budayanti, N. N. S., Prilandari, L. I., & Adhiputra, I. K. A. I. (2021). Antimicrobial resistance profile of MDR & non-MDR meropenem-resistant Pseudomonas aeruginosa isolates of patients in intensive care unit of tertiary hospital. Indonesian Journal of Tropical and Infectious Disease, 9(3), 152–159. https://doi.org/10.20473/ijtid.v9i3.30000
Lestari, D., Djajaningrat, H., Dari, F. W., & Handimulya, D. (2025). Sensitivitas antara antibiotik meropenem dan seftazidin terhadap Pseudomonas aeruginosa strain ATCC 15442 pada pasien pneumonia di RSUP Dr. Cipto Mangunkusumo Jakarta Pusat. Anakes: Jurnal Ilmiah Analis Kesehatan, 11(1), 1–9. https://doi.org/10.37012/anakes.v11i1.2500
Li, Y., Roberts, J. A., Walker, M. M., Aslan, A. T., Harris, P. N. A., & Sime, F. B. (2024). The global epidemiology of ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa: A systematic review and meta-analysis. International Journal of Infectious Diseases, 139, 78–85. https://doi.org/10.1016/j.ijid.2023.11.023
Lodise, T. P., Patel, N., Kwa, A., Graves, J., Furuno, J. P., & Graffunder, E. (2007). Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: Impact of delayed appropriate antibiotic selection. Antimicrobial Agents and Chemotherapy, 51(10), 3510–3515. https://doi.org/10.1128/AAC.00338-07
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., et al. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 18(3), 268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
Mendes, P. D., Paulo, S. E., Santos, C. M., Fonseca, A. B., Melo-Cristino, J., Pereira, Á. A., et al. (2024). Extensively drug-resistant Pseudomonas aeruginosa: Clinical features and treatment in a tertiary care hospital. Frontiers in Microbiology, 15, 1347521. https://doi.org/10.3389/fmicb.2024.1347521
Ng, L. M. S., & Abad, C. L. R. (2026). Antimicrobial susceptibility trends and mortality of Pseudomonas aeruginosa hospital-acquired pneumonia and ventilator-associated pneumonia among adult patients: A retrospective single-center study. Open Forum Infectious Diseases, 13(Suppl 1), S727–S728.
Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J., & Cheng, Z. (2019). Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnology Advances, 37(1), 177–192. https://doi.org/10.1016/j.biotechadv.2018.11.013
Paul, M., Carrara, E., Retamar, P., Tängdén, T., Bitterman, R., Bonomo, R. A., et al. (2022). ESCMID guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli. Clinical Microbiology and Infection, 28(4), 521–547. https://doi.org/10.1016/j.cmi.2021.11.025
Sitompul, P. A., Indriani, R., Rusli, A., Sundari, T., Rosamarlina, R., & Hartono, T. S. (2022). Antimicrobial sensitivity pattern from hospitalized pneumonia patients in national referral infectious disease hospital in Indonesia. Advances in Medicine, 2022, 3455948. https://doi.org/10.1155/2022/3455948
Tato, M., Coque, T. M., Ruiz-Garbajosa, P., Pintado, V., Cobo, J., Sader, H. S., et al. (2018). Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. Frontiers in Microbiology, 9, 46. https://doi.org/10.3389/fmicb.2018.00046
Watanabe, N., Mori, M., Yoshimura, K., Saito, K., Saito, S., Imai, Y., et al. (2018). Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. International Journal of Antimicrobial Agents, 52(5), 680–685. https://doi.org/10.1016/j.ijantimicag.2018.07.025
World Health Organization. (2017). Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. WHO.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 JURNAL RISET RUMPUN ILMU KESEHATAN
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
_001.jpg)
